Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

New Osteoarthritis Recommendations and Classification Criteria for Sjögren’s Syndrome and Polymyalgia Rheumatica

Kathy Holliman  |  Issue: April 2012  |  April 6, 2012

Another change from the previous ACR recommendations for OA management is that the 2012 document does not recommend a sequence of subsequent interventions if initial therapies for OA do not result in an adequate response. This change is due to a lack of high-quality studies that reliably examined the benefit and safety of treatment modalities that could support recommendations of a specific sequence of therapy.

According to Dr. Hochberg, nonpharmacologic and pharmacologic therapies were given “equal weighting” in panel deliberations and literature reviews for the 2012 recommendations. “The nondrug treatments were given a lot of attention because they are the cornerstone of the management approach to people with OA. We find [they are] often neglected in primary care because of the short amounts of time that providers have to interact with their patients,” he says.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Unlike the previous ACR recommendations, the 2012 document includes recommendations for management of symptomatic hand OA.

Key Recommendations

Dr. Hochberg highlighted some of the key points among the recommendations:

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
  • Topical rather than oral nonsteroidal antiinflammatory drugs (NSAIDs) should be used whenever possible for people over age 75 years, a recommendation in accord with the American Geriatric Society.
  • For hand OA, provision of assistive devices, use of thermal modalities and trapeziometacarpal joint splints, and use of oral and topical NSAIDs, tramadol, and topical capsaicin are conditionally recommended.
  • Also for management of hand OA, it is conditionally recommended that intraarticular therapies and opioids not be used.
  • Acetaminophen, recommended previously as initial therapy for knee and hip OA, is now only conditionally recommended among other pharmacologic agents, such as oral and topical NSAIDs, which can be used as initial therapy in patients with hip and knee OA.
  • Aerobic, aquatic, resistance exercises, and weight loss are strongly recommended for knee and hip OA.
  • For both knee and hip OA, nutraceuticals such as chondroitin sulfate, glucosamine, and topical capsaicin are conditionally recommended not to be used.
  • Tai chi is conditionally recommended for knee OA, as is acupuncture in certain situations; no recommendation is given for tai chi for hip OA.
  • Management is addressed for those patients who would normally be referred to orthopedic surgeons but who choose not to have a joint replacement or are not medically suitable for surgery.

Some of the recommendations may come as a surprise to rheumatologists, Dr. Hochberg predicts, including the recommendation related to topical therapy for knee OA for all age groups, and particularly for those over age 75. “I think most rheumatologists are not aware of it and have a feeling that it does not work as well as oral therapy,” he says, “However, the data from clinical trials indicate that it does work.”

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:Clinical Criteria/GuidelinesConditionsOsteoarthritis and Bone DisordersOther Rheumatic ConditionsSjögren’s Disease Tagged with:AC&RAmerican College of Rheumatology (ACR)Classification CriteriaGuidelinesOsteoarthritisPolymyalgia RheumaticarheumatologistSjogren's

Related Articles

    Two Inflammatory Conditions—Polymyalgia Rheumatica and Giant Cell Arteritis—Share Clinical Connection

    March 1, 2013

    Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) have common clinical and epidemiologic links, but they need not occur synchronously

    Polymyalgia Rheumatica: New Tricks for an Old Disease

    January 29, 2024

    Originally posted Feb. 13, 2023; reposted in conjunction with publication of the PMR supplement to the February 2024 issue of The Rheumatologist. PHILADELPHIA—Polymyalgia rheumatica (PMR) is a chronic inflammatory condition that almost exclusively affects individuals older than 50.1 First described in 1888, PMR has been a recognized rheumatic disease since at least 1957. Diagnosing the…

    How to Manage Polymyalgia Rheumatica

    December 16, 2015

    Recognizing the need to provide guidance on the current disparate management of polymyalgia rheumatica (PMR), the American College of Rheumatology (ACR), in collaboration with the European League Against Rheumatism (EULAR), recently published the first international set of recommendations for the screening, treatment and management of PMR.1,2 Specifically, the recommendations offer guidance on the use of…

    Permanent Vision Loss in Late Giant Cell Arteritis

    October 18, 2018

    Patients with polymyalgia rheumatica (PMR) or peripheral arthritis may require extra vigilance during treatment because of a suspected link to giant cell arteritis (GCA) and, potentially, permanent vision loss. “Development of giant cell arteritis after treating polymyalgia or peripheral arthritis: a retrospective case-control study,” a March 2018 study published in The Journal of Rheumatology, suggests…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences